Does the media refer more to BBIO or RCUS?

In the previous week, BridgeBio Pharma had 13 more articles in the media than Arcus Biosciences. MarketBeat recorded 22 mentions for BridgeBio Pharma and 9 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.15 beat BridgeBio Pharma's score of 0.70 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 9 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RCUS or AXSM?

In the previous week, Axsome Therapeutics had 4 more articles in the media than Arcus Biosciences. MarketBeat recorded 13 mentions for Axsome Therapeutics and 9 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.15 beat Axsome Therapeutics' score of 0.75 indicating that Arcus Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RCUS or ELAN?

In the previous week, Arcus Biosciences had 4 more articles in the media than Elanco Animal Health. MarketBeat recorded 9 mentions for Arcus Biosciences and 5 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.16 beat Arcus Biosciences' score of 1.15 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RDY or RCUS?

Arcus Biosciences has a consensus price target of $35.10, indicating a potential upside of 24.80%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Arcus Biosciences 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.58

Does the media refer more to RDY or RCUS?

In the previous week, Arcus Biosciences had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 9 mentions for Arcus Biosciences and 6 mentions for Dr. Reddy's Laboratories. Arcus Biosciences' average media sentiment score of 1.15 beat Dr. Reddy's Laboratories' score of -0.18 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Arcus Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SMMT or RCUS?

In the previous week, Arcus Biosciences had 6 more articles in the media than Summit Therapeutics. MarketBeat recorded 9 mentions for Arcus Biosciences and 3 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.67 beat Arcus Biosciences' score of 1.15 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Arcus Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Arcus Biosciences (RCUS) Competitors

$28.12 -0.80 (-2.75%)

Closing price 07/13/2026 03:59 PM Eastern

Extended Trading

$27.90 -0.23 (-0.81%)

As of 06:58 AM Eastern

Compare

RCUS vs. BBIO, AXSM, ELAN, RDY, and SMMT

Should you buy Arcus Biosciences stock or one of its competitors? MarketBeat compares Arcus Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arcus Biosciences include BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.

How does Arcus Biosciences compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Arcus Biosciences has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	32.41	-$724.93M	-$3.74	N/A
Arcus Biosciences	$247M	14.32	-$353M	-$3.18	N/A

BridgeBio Pharma presently has a consensus price target of $94.63, suggesting a potential upside of 13.90%. Arcus Biosciences has a consensus price target of $35.10, suggesting a potential upside of 24.80%. Given Arcus Biosciences' higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, BridgeBio Pharma had 13 more articles in the media than Arcus Biosciences. MarketBeat recorded 22 mentions for BridgeBio Pharma and 9 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.15 beat BridgeBio Pharma's score of 0.70 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	9 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Pharma has a net margin of -124.42% compared to Arcus Biosciences' net margin of -156.36%. BridgeBio Pharma's return on equity of 0.00% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

BridgeBio Pharma has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

Summary

BridgeBio Pharma beats Arcus Biosciences on 10 of the 16 factors compared between the two stocks.

How does Arcus Biosciences compare to Axsome Therapeutics?

Arcus Biosciences (NYSE:RCUS) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Axsome Therapeutics has higher revenue and earnings than Arcus Biosciences. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	14.32	-$353M	-$3.18	N/A
Axsome Therapeutics	$638.50M	18.40	-$183.17M	-$3.73	N/A

In the previous week, Axsome Therapeutics had 4 more articles in the media than Arcus Biosciences. MarketBeat recorded 13 mentions for Axsome Therapeutics and 9 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.15 beat Axsome Therapeutics' score of 0.75 indicating that Arcus Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcus Biosciences has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market.

Axsome Therapeutics has a net margin of -26.59% compared to Arcus Biosciences' net margin of -156.36%. Arcus Biosciences' return on equity of -68.97% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Arcus Biosciences currently has a consensus price target of $35.10, indicating a potential upside of 24.80%. Axsome Therapeutics has a consensus price target of $259.05, indicating a potential upside of 13.48%. Given Arcus Biosciences' higher probable upside, research analysts plainly believe Arcus Biosciences is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

Summary

Axsome Therapeutics beats Arcus Biosciences on 10 of the 17 factors compared between the two stocks.

How does Arcus Biosciences compare to Elanco Animal Health?

Arcus Biosciences (NYSE:RCUS) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

Arcus Biosciences has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

Arcus Biosciences currently has a consensus price target of $35.10, indicating a potential upside of 24.80%. Elanco Animal Health has a consensus price target of $28.55, indicating a potential upside of 13.61%. Given Arcus Biosciences' higher probable upside, equities analysts plainly believe Arcus Biosciences is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Arcus Biosciences had 4 more articles in the media than Elanco Animal Health. MarketBeat recorded 9 mentions for Arcus Biosciences and 5 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.16 beat Arcus Biosciences' score of 1.15 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elanco Animal Health has higher revenue and earnings than Arcus Biosciences. Elanco Animal Health is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	14.32	-$353M	-$3.18	N/A
Elanco Animal Health	$4.72B	2.66	-$232M	-$0.50	N/A

Elanco Animal Health has a net margin of -4.95% compared to Arcus Biosciences' net margin of -156.36%. Elanco Animal Health's return on equity of 7.42% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Elanco Animal Health	-4.95%	7.42%	3.66%

Summary

Elanco Animal Health beats Arcus Biosciences on 12 of the 17 factors compared between the two stocks.

How does Arcus Biosciences compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Dr. Reddy's Laboratories has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

Arcus Biosciences has a consensus price target of $35.10, indicating a potential upside of 24.80%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Dr. Reddy's Laboratories has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.02	$456M	$0.58	22.30
Arcus Biosciences	$247M	14.32	-$353M	-$3.18	N/A

In the previous week, Arcus Biosciences had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 9 mentions for Arcus Biosciences and 6 mentions for Dr. Reddy's Laboratories. Arcus Biosciences' average media sentiment score of 1.15 beat Dr. Reddy's Laboratories' score of -0.18 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Arcus Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Arcus Biosciences' net margin of -156.36%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 9.6% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Arcus Biosciences beats Dr. Reddy's Laboratories on 9 of the 16 factors compared between the two stocks.

How does Arcus Biosciences compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

In the previous week, Arcus Biosciences had 6 more articles in the media than Summit Therapeutics. MarketBeat recorded 9 mentions for Arcus Biosciences and 3 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.67 beat Arcus Biosciences' score of 1.15 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Arcus Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics has a beta of -1.26, meaning that its stock price is 226% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market.

Summit Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Arcus Biosciences' return on equity of -68.97% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Summit Therapeutics currently has a consensus target price of $26.97, indicating a potential upside of 76.29%. Arcus Biosciences has a consensus target price of $35.10, indicating a potential upside of 24.80%. Given Summit Therapeutics' higher probable upside, equities research analysts clearly believe Summit Therapeutics is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Comparatively, 9.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Arcus Biosciences has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Arcus Biosciences	$247M	14.32	-$353M	-$3.18	N/A

Summary

Arcus Biosciences beats Summit Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Arcus Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCUS vs. The Competition

Export

Metric	Arcus Biosciences	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$3.64B	$3.71B	$7.05B	$23.46B
Dividend Yield	N/A	2.20%	2.68%	4.02%
P/E Ratio	-8.84	20.85	27.11	31.08
Price / Sales	14.32	314.01	589.96	19.77
Price / Cash	N/A	61.98	29.22	18.64
Price / Book	4.82	8.49	10.74	4.77
Net Income	-$353M	$23.83M	$3.58B	$1.06B
7 Day Performance	-7.50%	-3.56%	-2.11%	-0.23%
1 Month Performance	17.92%	6.31%	3.27%	-0.11%
1 Year Performance	191.30%	48.30%	26.31%	16.46%

Arcus Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCUS Arcus Biosciences	3.891 of 5 stars	$28.13 -2.7%	$35.10 +24.8%	+200.8%	$3.64B	$247M	N/A	500	News Coverage Positive News Insider Trade Gap Down
BBIO BridgeBio Pharma	3.1187 of 5 stars	$77.75 +0.7%	$92.90 +19.5%	+78.8%	$15.12B	$502.08M	N/A	400	Trending News Analyst Forecast Insider Trade
AXSM Axsome Therapeutics	3.5238 of 5 stars	$242.60 -0.7%	$258.95 +6.7%	+109.5%	$12.57B	$638.50M	N/A	380
ELAN Elanco Animal Health	3.9066 of 5 stars	$25.12 +0.5%	$28.55 +13.6%	+68.7%	$12.49B	$4.72B	N/A	9,400	Gap Down
RDY Dr. Reddy's Laboratories	1.7289 of 5 stars	$14.36 -0.1%	N/A	-10.8%	$12.00B	$3.58B	24.76	27,527

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RCUS) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcus Biosciences (RCUS) Competitors

RCUS vs. BBIO, AXSM, ELAN, RDY, and SMMT

How does Arcus Biosciences compare to BridgeBio Pharma?

Summary

How does Arcus Biosciences compare to Axsome Therapeutics?

Summary

How does Arcus Biosciences compare to Elanco Animal Health?

Summary

How does Arcus Biosciences compare to Dr. Reddy's Laboratories?

Summary

How does Arcus Biosciences compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS vs. The Competition

Arcus Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcus Biosciences (RCUS) Competitors

RCUS vs. BBIO, AXSM, ELAN, RDY, and SMMT

How does Arcus Biosciences compare to BridgeBio Pharma?

Which has preferable earnings and valuation, BBIO or RCUS?

Do analysts rate BBIO or RCUS?

Do insiders & institutionals hold more shares of BBIO or RCUS?

Does the media refer more to BBIO or RCUS?

Is BBIO or RCUS more profitable?

Which has more risk & volatility, BBIO or RCUS?

Summary

How does Arcus Biosciences compare to Axsome Therapeutics?

Which has higher valuation and earnings, RCUS or AXSM?

Does the media prefer RCUS or AXSM?

Which has more volatility & risk, RCUS or AXSM?

Is RCUS or AXSM more profitable?

Do institutionals & insiders believe in RCUS or AXSM?

Do analysts prefer RCUS or AXSM?

Summary

How does Arcus Biosciences compare to Elanco Animal Health?

Which has more risk & volatility, RCUS or ELAN?

Do analysts recommend RCUS or ELAN?

Do institutionals and insiders hold more shares of RCUS or ELAN?

Does the media favor RCUS or ELAN?

Which has higher valuation & earnings, RCUS or ELAN?

Is RCUS or ELAN more profitable?

Summary

How does Arcus Biosciences compare to Dr. Reddy's Laboratories?

Which has more risk and volatility, RDY or RCUS?

Do analysts prefer RDY or RCUS?

Which has higher earnings and valuation, RDY or RCUS?

Does the media refer more to RDY or RCUS?

Is RDY or RCUS more profitable?

Do institutionals & insiders believe in RDY or RCUS?

Summary

How does Arcus Biosciences compare to Summit Therapeutics?

Does the media refer more to SMMT or RCUS?

Which has more risk & volatility, SMMT or RCUS?

Is SMMT or RCUS more profitable?

Do analysts prefer SMMT or RCUS?

Do insiders and institutionals believe in SMMT or RCUS?

Which has stronger earnings & valuation, SMMT or RCUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS vs. The Competition

Arcus Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools